NVS$168.62
$170.84
Chart
Performance
Key Stats
AI NVS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyNovartis AG presents a compelling investment case with a strong fundamental profile in the healthcare sector, supported by its diverse product portfolio and consistent dividend. While its thematic positioning is solid, recent technical indicators suggest a cautious short-term outlook.
Thematic
Novartis is a major player in global healthcare, benefiting from secular trends in aging populations, chronic disease management, and advancements in medicine. Its focus on cardiovascular, oncology, and immunology aligns with high-growth areas.
Fundamental
Novartis demonstrates robust financial health with solid profitability, consistent revenue growth, and a strong balance sheet. Its P/E ratio is within reasonable bounds for the pharmaceutical sector, and its dividend yield is attractive.
Technical
Novartis' stock is trading below key moving averages on a daily basis, with some oscillators indicating potential weakness. However, longer-term trends remain moderately positive.
| Factor | Score |
|---|---|
| Healthcare Demand (Aging Population) | 85 |
| Oncology & Immunology Growth | 80 |
| Cardiovascular & Metabolic Health | 75 |
| Innovation & R&D Pipeline | 70 |
| Regulatory & Pricing Pressures | 50 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 85 |
| Growth | 70 |
| Balance Sheet Health | 80 |
| Cash Flow | 90 |
| Dividend Yield | 85 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 45 |
| Support & Resistance | 70 |
| Inter-market Analysis | 75 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Surprises
Novartis AG has a history of beating earnings estimates, with reported EPS exceeding estimates in 11 out of the last 12 quarters, indicating operational strength and effective management.
Strong Free Cash Flow Generation
The company generated $13.8 billion in Free Cash Flow in 2024, which is a significant increase from $11.7 billion in 2023, providing ample flexibility for investments, debt reduction, or shareholder returns.
Bearish Points (7)
Increasing Quarterly P/E Ratio
The quarterly P/E ratios show an increasing trend in recent periods (e.g., from 64.5 in 2024Q4 to 58.0 in 2025Q2), which might suggest that current earnings are not keeping pace with the stock price appreciation.
Q1 2024 EPS Miss
The company missed earnings expectations in Q1 2024 (reported EPS of $1.53 vs. estimate of $1.69), which could signal potential challenges in meeting future projections.
Calendar
March 2025
12
Ex-Dividend Date
April 2025
25
Next Dividend Date
July 2025
17
Next Earnings Date
H: $2.31
A: $2.29
L: $2.28
H: 13.91B
A: 13.69B
L: 13.38B
Profile
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Seasonals
Price Target
115.90 USD
The 39 analysts offering 1 year price forecasts for NVS have a max estimate of 138.00 and a min estimate of 96.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in pharmaceuticals and diagnostics, particularly strong in oncology and immunology, areas where Novartis also has a significant presence. Both are major Swiss pharma companies.
Weight: 95
Global pharmaceutical giant with a diverse portfolio including vaccines, oncology, and internal medicine, making it a broad direct competitor across multiple therapeutic areas.
Weight: 92
Large diversified healthcare company with a substantial pharmaceutical segment that competes directly with Novartis in areas like immunology, oncology, and neuroscience.
Weight: 90
A leading pharmaceutical company known for its strong oncology franchise (e.g., Keytruda) and vaccines, which overlap with key strategic areas for Novartis.